A study published in Nature Medicine explored potential mechanisms of treatment resistance in patients with multiple myeloma following immunotherapies targeting B cell maturation antigen (BCMA) or ...

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nature Medicine, 2023; DOI: 10.1038/s41591-023-02491-5 ...

Gene set analyses identified point mutations and structural rearrangements in 11 NF-κB pathway genes, thereby supporting previous evidence for NF-κB signalling in multiple myeloma progression.

More information: Tumor Intrinsic Mechanisms of Antigen Escape to Anti-BCMA and Anti-GPRC5D Targeted Immunotherapies in Multiple Myeloma, Nature Medicine (2023). DOI: 10.1038/s41591-023-02491-5 ...

Drug resistance continues to be a major problem in proteasome inhibitor (PI) therapy for patients with multiple myeloma (MM). In a new review article, investigators outlined some of the latest ...

Proposed model of mechanism underlying the role of ADAR1 in regulating resistance to IMiDs in MM. Credit: Blood (2024). DOI: 10.1182/blood.2024024429 ...

Article: Nature Medicine - Tumor Intrinsic Mechanisms of Antigen Escape to Anti-BCMA and Anti-GPRC5D Targeted Immunotherapies in Multiple Myeloma. DOI: 10.1038/s41591-023-02491-5 # # # ...

This team analyzed 155 multiple myeloma samples and identified 10 genes where mutations were involved in the activation of the NF-kappaB pathway. The single most common abnormality was ...

"When the drugs were applied, all the other cells died, but those with these mutations became survivors," Haertle explains. To prevent the tumor from becoming resistant through this mechanism, the ...